Part IThe Story
From 1934 onward, the Eli Lilly and Company campus on McCarty Street in Indianapolis contained a building that was a copy of another building. The original stood at 15 West Pearl Street. It was a rented two-story structure, since demolished, where on May 10, 1876, a thirty-seven-year-old Union veteran with $1,400 in working capital, a fourteen-year-old son, and two hired hands began mixing medicines under a sign that read, with a pharmacist's economy, Eli Lilly, Chemist. Fifty-eight years later the company that had grown out of that room built a replica of it, and in the same year opened the Lilly Research Laboratories, which a company historian would call "one of the most fully equipped facilities in the world." A reliquary and a laboratory went up side by side: one facing backward toward a man, the other forward toward molecules nobody had yet named.
In 1953, a year after Lilly sold its first shares to the public on the New York Stock Exchange, the presidency of the firm passed to a man whose name had never been over any door on that campus. Eugene N. Beesley was in his mid-forties. He had graduated from Wabash College, forty-odd miles up the road in Crawfordsville, with the class of 1929. He was not a Lilly by birth or by marriage. For seventy-seven years the company had been run by four men of one bloodline: the Colonel, his son, and his two grandsons. Beesley was the fifth president, and he was the first who could walk past the replica laboratory without seeing his grandfather in it.
That is most of what can be said with certainty about why he matters, and almost all of it is about the people on either side of him. This is the problem with Eugene Beesley, and it is also the point. The family that hired him left its name on a library, a park, a museum, a foundation, a civil-war museum under the Soldiers' and Sailors' Monument, and the bottles in a great many American medicine cabinets. The man to whom they first handed the keys left a fraternity listing, a 1953 journal article, a folder in a university archive, a few lines in an encyclopedia table, and a New York Times obituary whose headline needed the family's name to explain who he was.
The company he was trusted to run is now worth more than a trillion dollars.
By the Numbers
The Inheritance and the Handoff
77 yearsFamily presidency of Eli Lilly and Company, 1876 to 1953
$1,400Colonel Lilly's working capital on Pearl Street, May 1876
$117MAnnual sales in 1948, up from $13 million in 1932
35Countries with Lilly employees by 1948
60%Share of Salk's polio vaccine Lilly manufactured in 1955
$39MLilly Endowment assets in 1948, after J. K. Lilly Sr.'s bequest
$1TLilly's market capitalization in November 2025, a first for a health-care company
A Name Is a Kind of Capital
The name on the Pearl Street sign belonged to a man who had already been ruined once.
Eli Lilly was born in Baltimore in 1838, the eldest of eleven children in a Methodist family that was prohibitionist and anti-slavery and moved to Indiana partly on principle. At sixteen, visiting relatives in Lafayette, he wandered into Henry Lawrence's Good Samaritan Drug Store and watched a man compound medicine. He stayed four years as an apprentice. Lawrence taught him chemistry and also, crucially, how to keep books. The Civil War made him a captain of artillery: he recruited his own unit, papered Indianapolis with posters promising the "crack battery of Indiana," and led six three-inch ordnance rifles and 150 men through Hoover's Gap, Chickamauga, and Mossy Creek. Several of his artillerymen thought him too young and intemperate to command. He became competent anyway. In September 1864 Nathan Bedford Forrest's cavalry captured him at Sulphur Creek Trestle in Alabama, and he spent four months in a prison camp at Enterprise, Mississippi.
After the war he stayed south and leased a 1,200-acre cotton plantation in Mississippi called Bowling Green. He brought his wife Emily, his sister, and his small son down from Greencastle. The family caught what was probably malaria. Emily died on August 20, 1866, eight months pregnant; the second son was stillborn. Lilly wrote home:
— Eli Lilly, in a letter to his family after Emily Lemen Lilly's death, 1866I can hardly tell you how it glares at me... it's a bitter, bitter truth... Emily is indeed dead.
He walked away from the plantation. A drought killed the cotton crop, and his partner disappeared with the remaining cash. In 1868 Eli Lilly filed for bankruptcy. His son Josiah, called J. K., went to live with grandparents in Greencastle.
Everything that came afterward, including the presidency Eugene Beesley would inherit eighty-five years later, carries the shape of that loss. The Colonel had seen what bad medicine did to soldiers. He had watched quinine-treatable fever take his wife. When he finally opened his own laboratory, one of the first drugs he made was quinine. He committed the firm to producing what he considered real medicine in a trade still dominated by patent remedies and miracle claims. He also pushed, earlier than most, for the idea that addictive or dangerous drugs should go only to people who had first seen a physician. He wanted federal regulation of his own industry, and many of the reforms he urged became law in 1906, eight years after his death, in the statute that created the Food and Drug Administration.
The business itself was assembled from scraps. A three-year manufacturing partnership with John F. Johnston ended on March 27, 1876, leaving Lilly with roughly $400 in merchandise (some equipment and a few gallons of unmixed chemicals) and about $1,000 in cash. Augustus Keifer, a wholesale druggist and family friend, told him to go out on his own, and Keifer and two associated drugstores agreed to buy from him at prices lower than they were already paying. That gave him a guaranteed customer, a discount, and a friend's push. Albert Hall was hired as chief compounder and Caroline Kruger as bottler and finisher. J. K., fourteen, quit school to apprentice to his father.
Sales for the remainder of 1876 came to $4,470. By 1879 they were $48,000. In 1878 the Colonel hired his brother James as the company's first full-time salesman. A cousin, Evan Lilly, kept the books. In 1881 the business was incorporated, a board was elected, and stock was issued "to family members and close associates." Two categories appear in that phrase, and the second, close associates, was where the future would come from. It was a very small door. It took seventy-two years for someone to walk all the way through it.
Three Generations Who Measured Things
A family firm usually does not survive its family. That this one did owes less to the founder's ethics than to his descendants' obsession with measurement.
J. K. Lilly Sr. came back from the Philadelphia College of Pharmacy in 1882 and became superintendent of the laboratory. In 1890 his father turned over day-to-day management, and J. K. ran the company for the next thirty-four years. He introduced scientific management, organized the research department, enlarged the sales force, and began selling abroad. By 1905 annual sales reached $1 million. In 1917 Scientific American described Lilly as "the largest capsule factory in the world," capable of producing 2.5 million capsules a day. He was not a romantic, and he did not need to be. His father had supplied the conscience. He supplied the machinery.
His sons supplied the systems that would eventually make the family unnecessary.
Eli, the elder, born in 1885, joined in 1909. That same year he introduced a method for blueprinting manufacturing tickets, which produced multiple identical copies of each drug formula so that nobody on the floor had to transcribe a recipe by hand. It is an unglamorous innovation. It is also the first piece of evidence that a Lilly had begun designing a company in which the right outcome no longer depended on the right person being in the room. In the 1920s he brought straight-line production to pharmaceuticals: raw materials entered at one end of a facility and finished product came out the other. Building 22, a five-story plant that opened in 1926, was built around the idea.
— Historian James H. Madison, on Lilly's Building 22It was probably the most sophisticated production system in the American pharmaceutical industry.
The efficiency had a human consequence that is easy to miss. Before straight-line production, Lilly recalled workers at peak times and laid them off when demand fell. Afterward it could keep a regular workforce, filling slack periods with lower-cost medicines made on the same lines. A machine built for throughput turned out to be a machine for stability.
Joe, eight years younger, who joined in November 1914 after a two-year pharmacy course at Michigan, was the brother who wrote things down about people. In 1916 he became head of a newly formed Efficiency Division responsible for employee relations, payroll, and methods and standards. Shortly after joining he wrote a long report on employment practice that became the basis of Lilly's personnel philosophy: fair wages, reasonable hours, favorable working conditions, good benefits. He was said to stress "the human side of business." He served in France in the First World War as a medical supply officer, came home, built a sales research department, and started running sales training courses at regular intervals. In the late 1920s he and Eli set up a Planning Department.
In 1919 or 1920, depending on which record you trust, J. K. Sr. hired a biochemist named George Henry Alexander Clowes as director of biochemical research. Clowes brought with him something the family could not produce on its own, which was standing in the scientific community. In December 1921 he proposed a collaboration to a group at the University of Toronto working on a pancreatic extract for diabetes. He was refused, and he asked again in March 1922 and again in May. The Toronto researchers were wary of commercial drug firms and had the non-commercial Connaught Laboratories at hand. When Connaught reached the limits of what it could produce, Clowes and Eli Lilly went north and negotiated a deal. In 1923 Lilly began selling Iletin, the first commercially available insulin in the United States, and held an effective monopoly for almost two years, until Frederick Stearns & Co. entered the market in June 1924. (Michael Bliss's The Discovery of Insulin remains the definitive account of how close the arrangement came to not happening.)
Insulin was, in the words of one history, "the most important drug" in the company's past, and it did "more than any other" to make Lilly a major manufacturer. It also set a template: the outside scientist, the university partner, the industrial scale that academia could not reach alone. By the company's fiftieth anniversary in 1926, sales had reached $9 million across more than 2,800 products. In 1928 came Liver Extract 343 for pernicious anemia, developed with George Minot and William P. Murphy of Harvard, and in 1930 Liver Extract No. 55 with George Whipple of Rochester. All three collaborators won the Nobel Prize in 1934. Joe's mother had suffered from pernicious anemia, and she died in 1934, the year the prize was awarded.
When Eli became president in 1932, sales were $13 million. When he stepped up to chairman in 1948, they were $117 million, and the workforce had grown from 1,675 to 6,912. In the war the company manufactured penicillin, Merthiolate, gas-gangrene antitoxin, typhus and influenza vaccines, and seasickness pills for D-Day. Working with the Red Cross, it dried more than two million pints of blood plasma, about a fifth of the national total. In 1943 it formed Eli Lilly International Corporation. By 1948 Lilly employees were working in thirty-five countries.
The grandsons had built a company of procedures, departments, tickets, and lines. Without quite intending it, they had built a company that could be run by someone who was not them.
The Son Who Walked Away
Succession in a family firm is usually settled by a birth. At Lilly it was settled, as far as the record shows, by a resignation.
Joe Lilly had two children. His daughter Ruth, born in 1915, became one of the great American philanthropists of her century; she gave away an estimated $800 million in her lifetime, most of it in Indiana. His son, Josiah Kirby Lilly III, born in 1916, joined the company in 1939, served in the Second World War, and came back to be superintendent of the Kentucky Avenue plant. That was a new facility. In 1945 Lilly had bought the enormous Curtiss-Wright propeller plant west of McCarty Street, and when renovation finished in mid-1947 it was making antibiotics and capsules and housing the shipping department. The fourth generation of Lillys was being tried out in a building converted from making propellers for warplanes.
He did not stay. Sources disagree on the year, 1946 or 1948, but they agree on the fact: Josiah III resigned and did not succeed his father. In 1954, after a brief term as secretary of the Lilly Endowment, he resigned from that as well and moved to New England. On Cape Cod he later founded Heritage Museums and Gardens in Sandwich, Massachusetts, in his father's honor. It displays, among other things, Joe's military miniatures.
Joe Lilly's biographers connect the resignation directly to what followed. The company's growing size, the complexity of the business, and Josiah III's departure "caused the company to consider a gradual leadership transition that would separate the company's ownership from its day-to-day management." The reorganization of 1944 had already prepared the ground, and the family had been building the legal machinery for that separation for most of a decade.
That machinery was the Lilly Endowment. In 1937 J. K. Sr. and his two sons organized it with gifts of company stock; the articles of incorporation were filed with the Indiana Secretary of State on June 25, 1937. The Revenue Act of 1935, effective January 1936, had sharply raised estate taxes on very large fortunes. The family's purposes, as the Encyclopedia of Indianapolis records them, were frankly twofold: to solidify "the family hold of the ancestral business" and to link the Lilly "name to a great benefaction for generations." The charter itself was simpler:
— Article III, Articles of Incorporation of Lilly Endowment, Inc., June 25, 1937the promotion and support of religious, educational or charitable purposes, or all of them.
For its first years the Endowment ran out of a desk drawer. Eli Lilly read the requests himself and made recommendations to a board consisting of himself, his father, his brother, his wife Ruth Allison Lilly, and Nicholas Noyes, the company treasurer, the only outsider at the table. The first grants were approved in December 1937; the largest was $10,500 to the Indianapolis Community Fund. Over the years J. K. Sr. gave stock worth $86.8 million, Joe $6 million, and Eli $2.8 million. When J. K. Sr. died in 1948, his bequest took the Endowment's assets from $9 million in 1947 to $39 million in 1948.
Taken together, the arrangement is clear. Ownership was going to flow into a foundation that bore the name, and management was going to flow to whoever could do the job. The 1952 public offering was the first piece of evidence that the family meant it. The second was Eugene Beesley.
Wabash, Class of 1929
At this point the record thins, and I should be candid about it.
There is no extended published biography of Eugene N. Beesley that I could find. Harvard Business School keeps a database called Great American Business Leaders of the 20th Century, and his name has a profile page in it, but the page does not record the years of his birth and death. Butler University's archive in Indianapolis lists a folder headed only "Beesley, Eugene N., 1966." A Beta Theta Pi alumni list of notable members in business places him alphabetically between Stephen D. Bechtel Sr. and an Episcopal bishop, with a single line: Eugene N. Beesley, Wabash '29, Former Chairman of the Board for Eli Lilly & Co. A bibliographic index records an article titled "The Drug Industry," by E. N. Beesley, published February 1, 1953, with zero recorded citations.
A New York Times obituary ran February 9, 1976: "Eugene N. Beesley Dead at 67; Ex-Chairman of Eli Lilly & Co."
Here is what can be built from that. He belonged to Wabash's class of 1929, the year the market broke, and so came of age professionally in the Depression. Wabash is a small men's college in west-central Indiana. Its graduates do not tend to be Philadelphia pharmacists or University of Michigan men with family stock. He was a Hoosier, and he was not a Lilly. He became president of the company in 1953, the year his essay on "The Drug Industry" appeared under his initials. That timing is suggestive: a man taking charge of a firm in the year he publishes a general argument about the industry it belongs to. I cannot tell you what the essay says, and I will not guess.
In a family firm, the first non-family president often has the more interesting biography in some other sense. He is the one who had to be chosen. The founder chose himself. The son was born to it, and the grandsons were sent on errands around the plant as boys, as the Colonel's grandsons were. The outsider has to be picked, and the act of picking reveals what the family valued once blood was off the table. The choice of Beesley, a Wabash man and an Indiana man who, in every surviving trace, kept quiet and stayed in the background, says that the Lillys valued continuity of temperament over novelty. They chose someone who resembled them in everything except surname.
Josiah K. Lilly Jr. had been president from 1948 to 1953. On Beesley's elevation, Joe became chairman of the board and stayed there until his death in 1966. So the first thirteen years of the professional era had a Lilly at the head of the board table. The outsider ran the floor and the family kept the chair. It is a familiar pattern in companies that manage the transition well, and it is rarely written down as a decision because by the time anyone thinks to write it down it has already worked.
At some later point Beesley himself became chairman. The obituary calls him ex-chairman, and so does the fraternity list. The exact year is not in the sources I have. By 1972 the presidency had passed to Burton E. Beck, and in that year, on Beck's retirement, Richard Donald Wood became president and chief executive. That is the line of succession as it can be documented: the Colonel, J. K., Eli, Joe, Beesley, Beck, Wood. There was no rupture at the point where the bloodline ends. That smoothness is the achievement.
The Year of the Vaccine
The first great test of the new presidency came out of the company's past.
In 1954 the National Foundation for Infantile Paralysis, the organization later known as the March of Dimes, contracted with five pharmaceutical companies to produce Jonas Salk's poliomyelitis vaccine for clinical trials: Lilly, Cutter Laboratories, Parke-Davis, Pitman-Moore, and Wyeth. Lilly was selected, according to the Indiana Historical Society's account, partly because of its record of collaborating with university researchers. That record went back through Whipple and Minot and Murphy to Clowes's three refused proposals to Toronto in 1921 and 1922. The family had built the credential and the outsider got to spend it.
In 1955, Lilly manufactured 60 percent of Salk's vaccine. Discover Indiana, drawing on the company archives, puts the figure for 1956 at 68 percent of the national supply. A polio outbreak in the early 1950s had disabled thousands of Americans, many of them children. By the 1960s case numbers in the United States had fallen dramatically. Lilly is remembered as the first company to mass-produce both insulin and the Salk vaccine. The first happened under J. K. Sr. and his son Eli; the second happened in the second year of the first president who was not related to either.
The rest of the decade went the same way. Lilly had launched Tippecanoe Laboratories in 1950 in Lafayette, the town where a sixteen-year-old Eli Lilly had first watched Henry Lawrence compound medicine, and had expanded antibiotic production under its erythromycin patent. In the 1950s it introduced vancomycin and erythromycin as products. In 1954, the same year as the polio contract, the company gathered its plant and animal science operations into an Agricultural and Industrial Sales Division. The division would later be renamed Elanco, would buy the animal-health businesses of Novartis for $5.4 billion in 2014 and Bayer for $7.6 billion in 2019, and in March 2019 would be spun off entirely. That was sixty-five years of compounding from a reorganization made in 1954.
None of this can be credited to Beesley alone, and it would be dishonest to try. Companies at that scale are not single people. But the first years of professional management at Lilly did not show the usual signs of a family firm in trouble: no flight of talent, no lurch into unrelated businesses, no collapse of research ambition into cost-cutting. What they showed was continuity. The president who had to be chosen ran the company as if he had been born to it.
What the Brothers Did Next
Joe Lilly's retirement from the presidency in 1953 has a quality the record calls simply "hobbies." The word does not cover it.
He had been collecting since boyhood. By the time he stepped aside he owned a Gutenberg Bible, a First Folio of Shakespeare, a double-elephant folio of Audubon's Birds of America, the Dunlap Broadside (the first printing of the Declaration of Independence), and a first edition of Poe's Tamerlane. He held ninety-four of the hundred titles on the Grolier Club's list of the most important books in English literature. He had manuscripts running from Robert Burns's "Auld Lang Syne" to J. M. Barrie's original Peter Pan. He collected gold coins, which went to the Smithsonian; nautical models, now at Mystic Seaport; eighteenth-century paintings; early automobiles; antique firearms; and stamps. He assembled a set of miniature soldiers representing every regiment that had served in the United States armies up to 1900, each in accurate uniform with correct flags, insignia, and arms. That last is the collection of a man whose grandfather once recruited a battery off handbills.
He built a special house to spend his days with all of it.
On November 26, 1954, he wrote to Herman B Wells, the president of Indiana University, describing his intention to give his general collection to the university. IU announced the gift on January 8, 1956; the Times valued it at $5 million. Lilly eventually gave more than 20,000 books, 17,000 manuscripts, more than fifty oil paintings, and 300 prints, and he paid for the building to hold them. The Lilly Library was dedicated in Bloomington on October 3, 1960. A photograph from the opening shows Joe Lilly beside Wells, opening the doors.
He had also, since 1934, been buying land along Eagle Creek northwest of Indianapolis until he held 3,469 acres. The estate, Eagle Crest, included a working farm, a nature preserve, and a thousand acres of forest in which he planted thousands of trees over twenty years. In 1936 he moved his books there. In 1958 he gave the whole property to Purdue. In 1966, the year he died, the city of Indianapolis bought it from the university and made it Eagle Creek Park, which has been called the largest city-owned and city-operated park and recreation area in the United States.
In the decade after 1953, then, the Lilly family turned its attention toward memory: curating, cataloguing, preserving, giving. Joe's daughter Ruth would spend the rest of a long life giving money away, including, famously, to poetry. His son was on Cape Cod. Eli the elder brother had his own historical passions; James H. Madison's Eli Lilly: A Life, 1885–1977 is the essential account of the grandson who managed the Endowment out of a drawer. The family members stopped being operators and became custodians of the past.
Someone had to run the present, and that was the job they had given Eugene Beesley.
There is a version of this story in which the family's retreat into collecting amounts to abdication, rich men's sons buying Gutenbergs while a hired hand runs the factory. That version doesn't fit the facts. The Lillys left in an orderly way. They kept the board chair for thirteen years, kept the stock in a foundation, chose a successor in their own image, and then spent their remaining energy on public goods that would carry the name into places the company could not reach: a library, a park, a museum. Their exit was planned as carefully as Building 22.
A Company That Could Survive Its Founders
What the professional era brought, over the half-century after Beesley, was what professional eras usually bring: scale, reach, and a slow drift away from the founder's reasons for doing things.
In the 1960s Lilly moved further abroad. It established a major factory in Liverpool in 1962, built its first research facility outside the United States, the Lilly Research Centre in Surrey, in 1968, and opened a plant in Clinton, Indiana, in 1969. In 1971 it bought Elizabeth Arden, the cosmetics company, for $38 million. Arden lost money for five years, then recovered; by 1982 its sales were up 90 percent from 1978 and profits had doubled to nearly $30 million, and in 1987 Lilly sold it to Fabergé for $657 million. Through the late 1970s and 1980s the company bought medical-device firms: IVAC, Cardiac Pacemakers for $127 million, Physio-Control, Advance Cardiovascular Systems for $85 million in stock, Hybritech for $350 million. In 1994 it separated the device business. It made Keflex, Ceclor, Dobutrex, and in 1988 Prozac.
Then came a stretch of instability that a family firm might never have permitted. Vaughn Bryson became president and chief executive in 1991, and during his twenty months the company reported its first quarterly loss as a public company. In 1993 the board did something it had not done in 117 years and went outside: Randall L. Tobias, vice chairman of AT&T and a Lilly director, became chairman, president, and CEO, the first chief executive recruited from outside the company. That year marks Lilly's second succession break. The first, in 1953, crossed the line of blood. The second, in 1993, crossed the line of the institution itself.
The professional era also produced the company's worst moments. In December 2005 Lilly pleaded guilty and paid $36 million over the illegal off-label promotion of Evista. In January 2009 it pleaded guilty to illegally marketing Zyprexa for off-label uses, particularly for dementia in the elderly, and agreed to pay $1.415 billion, including a $515 million criminal fine that the Justice Department called the largest ever in a health-care case and the largest criminal fine ever imposed on a single corporation in a United States prosecution of any kind. It is hard to read that alongside the Colonel's founding premise, which was to make medicines that did what they said, in a trade full of men who claimed otherwise, without registering the distance.
John Lechleiter, chief executive at the time, called it "a blemish." He said the company had put "systems in place." The phrase recalls the blueprint tickets of 1909: when you can no longer count on the right person being in the room, you build a process that does not need one. The Times later reported a Lechleiter email urging that the company "seize the opportunity to expand our work with Zyprexa" in the child-adolescent population for off-label use, which shows how much weight those systems have to carry.
And then the long arc bent upward again, and steeply. In 2005 Lilly brought exenatide to market, the first GLP-1 receptor agonist, derived from a substance isolated from Gila monster venom. Tirzepatide followed as Mounjaro in May 2022 and as Zepbound for obesity in November 2023. By 2025 it accounted for 56 percent of revenues. Revenue that year was $65.18 billion, with 50,000 employees and sales in roughly 125 countries. In November 2025 Lilly became the first health-care company in the world to reach a trillion-dollar market capitalization.
The largest single owner, at 9.8 percent, is still the Lilly Endowment.
The Keeper of the Family's Fortune
The Endowment's own history contains the most telling fact about Eugene Beesley.
After J. K. Sr.'s 1948 bequest, the foundation outgrew its drawer. Annual grants exceeded $2.6 million in 1951 alone, and the board concluded it needed a full-time staff. Josiah III worked there briefly before leaving for New England in 1954. Joe was its president from 1948 until his death in 1966. Eli, the elder brother, the one who had blueprinted the tickets and laid out the straight line, became president in 1966 and held the post until 1971.
The Endowment's table of officers then shows this:
Eli Lilly — President, 1966 to 1971; Chairman, 1972 to 1974; Honorary Chairman, 1975 to 1977.
Eugene N. Beesley — President, 1972 to 1974; Chairman and CEO, 1975 to 1976.
In 1972 the last surviving grandson of the founder, then eighty-six or eighty-seven, gave the presidency of the family's foundation to the man the family had first trusted with the company two decades earlier. In 1975 he gave him the chairmanship as well and took the honorary title for himself. The purpose recorded in 1937 had been to secure "the family hold of the ancestral business" and to link the name "to a great benefaction for generations." The family put that purpose, the stock and the name and the benefaction, into the hands of someone who did not carry the name.
Trust on that scale is not given to an employee. It is given to someone the family has come to regard as one of them.
Beesley did not hold the post for long. The table gives his chairmanship as ending in 1976, and the Times obituary is dated February 9 of that year. Landrum R. Bolling served as the Endowment's president from 1975 to 1976, and Thomas H. Lake took over in 1977. Eli Lilly, honorary chairman, outlived him by about a year, and Madison's biography dates Eli's life to 1977. The outsider died first, holding the family's trust, while the family's last grandson was still alive to see it.
Dead at 67
There is a kind of American career that is nearly impossible to profile. It belongs to the steward: the person who takes over something built by someone else, keeps it intact, enlarges it, hands it on, and leaves almost nothing behind with his own name on it. The founders get monuments, and the heirs get libraries and parks and museums named for them. The steward gets an entry in a table.
The Lilly family, from the Colonel's bankruptcy in 1868 to Ruth Lilly's death in 2009, worked steadily to turn its name into something durable: a sign over a door, then a brand, then an endowment, then a library on a campus in Bloomington, a park on Eagle Creek, and a Civil War museum under the monument the Colonel helped fund. In 1934 the company built a full replica of its first laboratory, and in 2016 the Indiana Historical Society built another, with costumed interpreters playing the Colonel and Caroline Kruger and Augustus Keifer for schoolchildren.
No one has built a replica of anything Eugene Beesley touched, and no costumed interpreter plays him. He may be the most consequential person in the company's history whose face nobody in Indianapolis could pick out.
What remains is the headline the New York Times set in type on February 9, 1976, which has to name two things to identify one man: his own name first, then a semicolon, then theirs.
Eugene N. Beesley Dead at 67; Ex-Chairman of Eli Lilly & Co.
Part IIThe Playbook
The record of Eugene Beesley's tenure is thin, but the record of the transition he embodied is detailed, documented, and unusually instructive. Lilly is one of the few great American family enterprises that moved from founder to dynasty to professional management to outside leadership without a crisis at the first handoff. What follows are the principles that explain how. They are drawn from what the family built to make Beesley possible, from what the company did once he arrived, and from what happened as each generation moved further from the original sign over the door.
The principles
- 1.Build the systems that make you replaceable.
- 2.Separate ownership from management with structure, not sentiment.
- 3.Open the capital first, then the corner office.
- 4.Keep the family in the chair while the outsider runs the floor.
- 5.Choose a successor who resembles you in everything but name.
- 6.Inherit the collaboration model, not just the product line.
- 7.Diversify from adjacent capabilities.
- 8.Give the heirs a dignified exit.
- 9.Treat the resignation as the signal.
- 10.Engineer the founder's ethics; don't assume them.
- 11.Let the institution carry the name.
Principle 1
Build the systems that make you replaceable
The handoff to Eugene Beesley in 1953 started with a blueprint machine in 1909. When the young Eli Lilly began making identical duplicates of manufacturing tickets, he removed a dependency: no worker needed to hold a formula in memory or copy it by hand, so no single person's carelessness could alter a dose. Straight-line production in Building 22 extended the same logic to physical flow. Joe's Efficiency Division and Planning Department extended it to people and procedures.
None of these were succession plans. Taken together they produced a company that could be run by someone without inherited knowledge, because the knowledge had been moved out of individuals and into process. Founders who keep critical judgment in their own heads protect their position and doom their succession. The Lillys, whether they meant to or not, did the reverse.
Tactic: Identify the three decisions in your company that currently depend on your personal memory or judgment, and turn each into a documented process someone else could run next quarter.
Principle 2
Separate ownership from management with structure, not sentiment
The Lilly Endowment was created in 1937 for reasons the family stated plainly: to protect "the family hold of the ancestral business" in the face of new estate taxes, and to tie the name to lasting philanthropy. Those purposes look like they conflict. They resolve once you see that the Endowment let the family keep economic and reputational control while giving up operational control. Stock flowed into a foundation that the family directed. Management could then flow to whoever was most capable.
Families that try to separate ownership and management through goodwill, informal understandings, or a patriarch's assurances usually fail when the patriarch dies. The Lillys built a legal entity first and then let the transition happen inside it. The 1944 reorganization, which explicitly prepared for "the eventual separation of company management from its ownership," came seven years after the Endowment existed.
Tactic: Before you discuss who will run the company after you, settle in writing who will own it and how that ownership will be governed.
Principle 3
Open the capital first, then the corner office
Lilly sold its first public shares in 1952. Beesley became president in 1953. The order matters. A public listing imposes external scrutiny, reporting discipline, and a constituency of owners who are not family. It gets the institution used to answering to strangers before a stranger is put in charge of it.
Reverse the order and you get a non-family president serving at the pleasure of a closed family board, which is a fragile arrangement and usually a short one. With the public offering first, the new president arrives with a mandate that extends beyond the family's goodwill.
L
The Lilly Succession, 1876–2016
Each handoff crossed a different boundary: generation, bloodline, and finally the institution itself.
1876
Colonel Eli Lilly opens his laboratory at 15 West Pearl Street with $1,400 in working capital.
1881
Firm incorporated; stock issued to family members and close associates.
1890
J. K. Lilly Sr. takes over day-to-day management; becomes president in 1898.
1932
Grandson Eli Lilly becomes president; sales are $13 million.
1937
Lilly Endowment incorporated with gifts of company stock.
1944
Reorganization prepares the separation of management from ownership.
1948
Josiah K. "Joe" Lilly Jr. becomes president; sales reach $117 million.
1952
First public shares traded on the New York Stock Exchange.
1953
Eugene N. Beesley becomes the first non-family president; Joe Lilly becomes chairman.
1966
Joe Lilly dies; remains chairman until his death.
1972
Richard D. Wood succeeds Burton E. Beck as president and CEO; Beesley becomes president of the Lilly Endowment.
1993
Randall L. Tobias becomes the first CEO recruited from outside the company.
2016
David A. Ricks succeeds John C. Lechleiter.
Tactic: If you plan to hand leadership to a non-family executive, introduce an outside constituency (investors, independent directors, or audited reporting) at least a year before the handoff.
Principle 4
Keep the family in the chair while the outsider runs the floor
From 1953 to 1966 Joe Lilly was chairman and Eugene Beesley was president. That thirteen-year overlap is the least visible and probably most important feature of the transition. It gave the new president legitimacy, because the family had visibly endorsed him and stayed at the table. It gave the family reassurance, because they could watch without having to manage. And it gave the organization time to get used to taking orders from someone named Beesley.
The overlap also had an end. Joe did not turn the chairmanship into a shadow presidency. The record suggests he spent his energy on books, land, and the Lilly Library. A family chairman who keeps second-guessing the professional president makes the overlap worse than a clean break. The skill is to be present without interfering.
Tactic: If you step back from operations but stay as chair, write down what decisions you will no longer make, and share that list with your successor on day one.
Principle 5
Choose a successor who resembles you in everything but name
Beesley was an Indiana man from an Indiana college who left almost no public record and appears in every surviving trace as a steward rather than a showman. The family did not bring in a celebrity executive from New York or a disruptor from another industry. They picked someone whose temperament matched the institution's.
There is a time for the outsider who breaks things. Lilly reached that point in 1993, after a quarterly loss and a twenty-month tenure that had not worked, and brought in Randall Tobias from AT&T. In 1953, though, the company was healthy, growing, and producing a large share of the nation's polio vaccine. The first non-family leader of a healthy firm should be chosen for continuity.
S
Three Kinds of Succession
The Lilly record shows three distinct handoffs, each suited to its moment.
| Handoff | Type | Condition of the firm | What it required |
|---|---|---|---|
| Colonel to J. K. Sr. (1890) | Family | Small, growing, founder-driven | A trained heir with technical education |
| Eli to Joe (1948) | Family | Large, wartime-expanded, global | Division of labor between production and people |
| Joe to Beesley (1953) | Insider | Healthy, newly public, heir departed | Continuity of temperament; family in the chair |
| Bryson to Tobias (1993) | Outsider | First quarterly loss as a public company | External perspective; break from internal habits |
Tactic: Before choosing a successor, decide whether the company needs continuity or correction, and recruit for that answer rather than for the most impressive résumé.
Principle 6
Inherit the collaboration model, not just the product line
Lilly was chosen as one of five polio-vaccine manufacturers in 1954 partly because of its experience working with university researchers. That experience was not a product. It was a capability and a reputation, built by George Clowes's persistent proposals to Toronto between 1921 and 1922 and renewed through the liver-extract work with Harvard and Rochester. By 1955 it had turned into 60 percent of Salk's vaccine.
A new leader taking over a successful firm will be tempted to see the inheritance as a portfolio of products. The more valuable inheritance is often the method that produced them. The company that mass-produced insulin in 1923 was the company that could mass-produce polio vaccine in 1955, because the habit of serving as industrial partner to academic science had become part of its identity.
Tactic: List the relationships and methods that produced your company's three best outcomes, and protect those as carefully as the products themselves.
Principle 7
Diversify from adjacent capabilities
In 1954, in the first full year of professional management, Lilly organized its existing plant and animal science work into a separate division. That division became Elanco, which over sixty-five years grew into a major animal-health company, bought Novartis's and Bayer's animal businesses, and was spun off in 2019. The diversification worked because it started from capabilities the firm already had.
Later diversifications had mixed results. Elizabeth Arden, bought in 1971, lost money for five years before recovering and selling for $657 million. Medical devices, acquired across the late 1970s and 1980s, were separated in 1994. Cosmetics and pacemakers shared less with a pharmaceutical laboratory than plant science did. The lesson is not that distant moves always fail. It is that adjacent moves compound and distant moves have to be rescued.
Tactic: Before entering a new business, name the existing internal capability it grows from; if you can't name one, treat the move as a separate venture with its own exit plan.
Principle 8
Give the heirs a dignified exit
The Lilly family left operations without bitterness, and much of the credit belongs to the exits they had available. Joe had his collections and the library he built for them. Ruth had philanthropy on an enormous scale. Josiah III had New England and the museum he founded in his father's honor. Eli had the Endowment and his historical interests. Each heir had somewhere meaningful to go.
Family firms often fail in transition because the family has nowhere to go but the boardroom, and so stays there, interfering. When the heirs have serious, well-resourced outlets that carry the family name into public life, they stop needing the company to give their lives meaning. That frees the professional manager to run it.
Tactic: If you own a family business, build at least one serious non-operating institution (a foundation, a fund, a civic project) in which family members can lead before they're asked to step back.
Principle 9
Treat the resignation as the signal
According to Joe Lilly's biographers, the decision to separate ownership from management was prompted in part by Josiah III's resignation. The family did not try to force the fourth generation back in or install a reluctant heir. They read the departure as information: the line of willing, capable family operators had ended, and the institution had to adjust.
The common mistake is to treat an heir's unwillingness as a problem to fix by persuasion, guilt, or a softened role. The Lillys treated it as a fact about the future and acted within a few years: reorganization, public offering, outside president.
Tactic: When the person you assumed would succeed you signals reluctance, take it at face value and start the alternative plan within twelve months.
Principle 10
Engineer the founder's ethics; don't assume them
Colonel Lilly founded his company on an argument about honesty in a trade full of quackery. He wanted medicines that worked as advertised and federal regulation of his own industry. A century later the company he founded pleaded guilty to illegal off-label promotion twice in four years, once for Evista and once for Zyprexa, the latter producing the largest criminal fine ever imposed on a single corporation in a U.S. prosecution at that time.
Professional management does not cause ethical drift by itself, but it removes the most direct protection against it, which is the founder's personal stake in the name. When the person running the company is not the person on the sign, the ethics need to be built into systems. Lechleiter's response after the Zyprexa plea, "systems in place," was correct and came late. The 1909 blueprint tickets had already shown that the reliable way to prevent errors is to design processes that don't depend on individual virtue.
Tactic: For every value your founder held personally, write down the specific control (a review, an audit, a veto) that will enforce it after the founder is gone.
Principle 11
Let the institution carry the name
Eugene Beesley is barely remembered, and that is arguably evidence he did the job well. His name is on no building. A Harvard database that profiles him does not record the years of his birth and death. His obituary needed the company's name to identify him. Yet he ran the firm through the polio years, became its chairman, and then led the family's own foundation, a trust the last surviving grandson gave him in 1972 and enlarged in 1975.
Some leaders build institutions around themselves, and those institutions often weaken when the leader leaves. Others disappear into the institution and leave it stronger. The second type rarely gets profiled, because there is little to say beyond the fact that things went well. For someone who inherits a great name, the right goal is to make that name more durable, not to compete with it.
Tactic: Measure your leadership by what the institution can do without you five years after you leave, not by how often your name appears while you're there.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
Eugene Beesley left almost no public words in the record available for this profile. The voices below belong to the institution he inherited and looked after: its founder, its charter, its historian, and one of its later chief executives.
— Historian James H. Madison, on Lilly before its turn to scienceAlthough the Indianapolis firm was more careful in making and promoting drugs than the patent medicine men of the era, the company remained ambivalent about scientific research.
— John C. Lechleiter, CEO of Eli Lilly and Company, on the Zyprexa settlementThat was a blemish for us. We don't ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but we have systems in place to support that.
Maxims
- Succession starts decades early. The blueprint tickets of 1909 were the first step toward the outside president of 1953.
- Own through structure. A foundation can keep a family's hold on a business long after the family has stopped running it.
- Go public before you go outside. Let the institution get used to answering to strangers before a stranger takes charge.
- Overlap, then let go. A family chair beside a professional president works only if the chair knows what it has given up.
- Choose continuity when nothing is broken. Bring in the disruptive outsider when there is something to fix, not before.
- Your methods are your real inheritance. The insulin partnership is what won the polio contract thirty years later.
- Grow from what you already do. Adjacent diversification compounds over decades; distant diversification usually has to be rescued.
- Give the heirs somewhere to go. A family with meaningful work outside the company will stop interfering with it.
- Systems outlast virtue. The founder's ethics survive only if they are built into procedures.
- Stewards rarely get monuments. Judge a successor by how well the name survives, not by how often the successor's own name appears.
